GILEAD SCIENCES, INC.

GILDSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 882095

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$27.1B	$27.3B	$27.3B	$24.7B	$22.4B
Cost of Goods and Services Sold	$6.5B	$5.7B	$6.6B	$4.6B	$4.7B
Gross Profit	—	—	—	—	—
Research and Development Expense	—	—	—	—	—
Selling, General and Administrative Expense	$6.1B	$5.7B	$5.2B	$5.2B	$4.4B
Operating Income (Loss)	$7.6B	$7.3B	$9.9B	$4.1B	$4.3B
Interest Expense	—	—	$1.0B	$984.0M	$995.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$59.0B	$62.1B	$63.2B	$68.0B	$68.4B
Assets, Current	$19.2B	$16.1B	$14.4B	$14.8B	$16.0B
Cash and Cash Equivalents, at Carrying Value	—	—	—	$5.3B	$6.0B
Accounts Receivable, after Allowance for Credit Loss, Current	$4.4B	$4.7B	$4.8B	$4.5B	$4.9B
Inventory, Net	$1.7B	$1.8B	$1.5B	$1.6B	$1.7B
Liabilities, Current	$12.0B	$11.3B	$11.2B	$11.6B	$11.4B
Long-term Debt	$26.7B	$25.0B	$25.2B	$26.7B	$31.4B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$8.0B	$9.1B	$11.4B	$8.2B	$9.1B
Net Cash Provided by (Used in) Investing Activities	-$2.3B	-$2.5B	-$3.1B	-$14.6B	-$7.8B
Net Cash Provided by (Used in) Financing Activities	-$5.1B	-$6.5B	-$8.9B	$770.0M	-$7.6B
Payments to Acquire Property, Plant, and Equipment	$585.0M	$728.0M	$579.0M	$650.0M	$825.0M
Payments of Dividends	$3.8B	$3.7B	$3.6B	$3.4B	$3.2B
Payments for Repurchase of Common Stock	$1.0B	$1.4B	$546.0M	$1.6B	$1.7B

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)